The end of hair loss during chemo?

Scientists from the University of Manchester found human scalp hair follicles (shown in pink) were less able to divide when exposed to anti-cancer drugs called CDK4/6 inhibitors.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractNigella glandulifera Freyn et Sint (N. glandulifera) is frequently added tonaan (a kind of crusty pancake and a favorite food of the Uyghur and Kazak people) as a spice. The water decoction ofN. glandulifera was used as traditional Uighur medicine to treat tinnitus, amnesia, amenorrhea, hypogalactia, heat stranguria, urethral calculus, alopecia and hair-blacking, edema, and bronchial asthma. This review aimed to give an updated, comprehensive summary on the traditional uses, pharmacology, phytochemistry and toxicology ofN. glandulifera to provide some reminders for future research. More than 78 chemical compounds w...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Capsule Summary: Spironolactone has a good long-term safety profile and has not been shown to increase the risk of developing cancer. Spironolactone may be a viable treatment option for alopecia in women who are under breast cancer remission and is not associated with an increased risk for breast cancer recurrence.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
CONCLUSIONS: The addition of TAK-228 to alisertib potentiates the anti-tumor activity of alisertib in vivo, resulting in increased cell death and apoptosis. The combination is tolerable in patients with advanced solid tumors and should be evaluated further in expansion cohorts with additional pharmacodynamic assessment. PMID: 32414750 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractThe efficacy of minoxidil (MXD) ethanolic solutions (1% ‐5% w/v) in the treatment of androgenetic alopecia is limited by adverse reactions. The toxicological effects of repeated topical applications of escalating dose (0.035%‐3.5% w/v) and of single and twice daily doses (3.5% w/v) of a novel hydroxypropyl‐β‐cyclodextrin MXD GEL formulation (MXD /HP‐β‐CD) and a MXD solution were investigated in male rats. The cardiovascular effects were evaluated by telemetric monitoring of ECG and arterial pressure in free‐moving rats. Ultrasonographic evaluation of cardiac morphology and function, and hist...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractPurposeCranial irradiation results in cognitive decline, which is hypothesized to be partially attributable to hippocampal injury and stem cell loss. Recent advances allow for targeted reduction of radiation dose to the hippocampi while maintaining adequate dose coverage to the brain parenchyma and additional increasing dose to brain metastases, a approach called hippocampal avoidance whole brain radiation therapy with a simultaneous integrated boost (HA-WBRT  + SIB.) We review our early clinical experience with HA-WBRT + SIB.Materials and methodsWe evaluated treatments and clinical outc...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: V20Gy and V40Gy were the strongest predictors for acute and chronic G2 hair-loss, respectively. The low-dose bath typical of VMAT corresponds to large areas of acute but transient alopecia. However, the steep dose gradient of VMAT allows to reduce the areas of the scalp that receive higher doses, minimizing the risk of permanent alopecia.The application of our dosimetric findings for the scalp may help in reducing the alopecia risk and also in estimating the probability of hair-loss during patient counseling before starting radiotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Spironolactone is safe for the treatment of alopecia in breast cancer survivors taking endocrine therapy, new research shows.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news
Conclusions: This nationwide, population-based study indicates that symptom burden is high in oesophageal cancer survivors 1 year after surgery. The most common problems are associated with food intake, sleep, fatigue and anxiety. However, less frequent symptoms were sometimes more debilitating for the individual patient. PMID: 32193960 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Alopecia | Cancer | Cancer & Oncology | Health